Serum Soluble Interleukin-2 Receptor as a Potential Biomarker for Immune-related Adverse Events
- 30 January 2021
- journal article
- research article
- Published by Anticancer Research USA Inc. in Anticancer Research
- Vol. 41 (2), 1021-1026
- https://doi.org/10.21873/anticanres.14857
Abstract
Background/Aim: Biomarkers for immune-related adverse events (irAEs) induced by immune checkpoint inhibitors (ICIs) are required. We encountered a patient whose skin irAE fluctuated in parallel with serum soluble interleukin-2 receptor (sIL-2R). Patients and Methods: We examined 15 patients with cancer who received ICIs. Serum sIL-2R levels before and during ICI treatment were measured. The sIL-2R levels of preserved serum samples from another five patients who developed grade 3 irAEs were measured. Results: Twelve patients showed no significant changes in sIL-2R levels during ICI treatment. Baseline serum sIL-2R levels in three patients increased beyond the normal range before the second cycle. These three patients had grade ≥2 irAEs at the second cycle treatment visit, supporting our hypothesis. Furthermore, at diagnosis of irAEs, the sIL-2R levels of all preserved samples from patients with grade 3 irAEs were significantly elevated. Conclusion: Serum sIL-2R is a promising biomarker for the diagnosis of irAEs.This publication has 20 references indexed in Scilit:
- Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-α is a biomarker of nivolumab recativityJournal of Dermatological Science, 2016
- Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanomaJournal for ImmunoTherapy of Cancer, 2015
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer TherapyCancer Cell, 2015
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Serum soluble interleukin 2 receptor α in human cancer of adults and children: a reviewBiomarkers, 2008
- On the Role of sIL-2R Measurements in Rheumatoid Arthritis and CancersMediators of Inflammation, 2005
- The Clinical Significance of Autoantibody Profiles in Patients with Systemic Lupus ErythematosusLupus, 1993
- Clinical significance of soluble interleukin 2 receptor for monitoring the diseases associated with activated lymphocytes and viral infectionsJournal of Clinical Laboratory Analysis, 1992
- The Soluble Interleukin-2 Receptor: Biology, Function, and Clinical ApplicationAnnals of Internal Medicine, 1990
- Prolonged Elevations of Soluble lnterleukin-2 Receptors in TuberculosisAmerican Review of Respiratory Disease, 1989